Comprehensive genomic analyses have indicated that mutation profiles, including the frequencies of TP53 and CTNNB1 mutations, which act as major oncogenic drivers, rather than drug targets in HCC, vary among subtypes (49). Here, TP53 is linked to hepatocellular carcinoma.